Association Between Influenza Vaccination and SARS-CoV-2 Infection.
Humans
Female
Pregnancy
COVID-19
/ prevention & control
Influenza Vaccines
/ immunology
Adult
Retrospective Studies
SARS-CoV-2
/ immunology
Pregnancy Complications, Infectious
/ epidemiology
Influenza, Human
/ prevention & control
Vaccination
Pregnancy Outcome
Infant, Newborn
Young Adult
Severity of Illness Index
COVID‐19
SARS‐CoV‐2
coronavirus
disease
infection
influenza
pregnancy
Journal
American journal of reproductive immunology (New York, N.Y. : 1989)
ISSN: 1600-0897
Titre abrégé: Am J Reprod Immunol
Pays: Denmark
ID NLM: 8912860
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
12
02
2024
accepted:
11
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
12
7
2024
Statut:
ppublish
Résumé
Recent data in nonpregnant individuals suggest a protective effect of influenza vaccination against SARS-CoV-2 infection and its severity. Our primary objective was to evaluate whether influenza vaccination was associated with COVID-19 severity and pregnancy and neonatal outcomes among those infected with SARS-CoV-2. The secondary objective was to examine the association between influenza vaccination and SARS-CoV-2 infection. Secondary analysis of a multicenter retrospective cohort of pregnant people who tested positive for SARS-CoV-2 between March and August 2020, and a cohort of random deliveries during the same time period. The associations between 2019 influenza vaccination and the primary outcome of moderate-to-critical COVID-19 as well as maternal and perinatal outcomes were examined among all people who tested positive for SARS-CoV-2 between March and August 2020. The association between 2019 influenza vaccination and having a positive SARS-CoV-2 test was examined among a cohort of individuals who delivered on randomly selected dates between March and August 2020. Univariable and multivariable analyses were performed. Of 2325 people who tested positive for SARS-CoV-2, 1068 (45.9%) were vaccinated against influenza in 2019. Those who received the influenza vaccine were older, leaner, more likely to have private insurance, and identify as White or Hispanic. They were less likely to smoke tobacco and identify as Black. Overall, 419 (18.0%) had moderate, 193 (8.3%) severe, and 52 (2.2%) critical COVID-19. There was no association between influenza vaccination and moderate-to-critical COVID-19 (29.2% vs. 28.0%, adjusted OR 1.10, 95% CI 0.90-1.34) or adverse maternal and perinatal outcomes among those who tested positive. Of 8152 people who delivered in 2020, 4658 (57.1%) received the influenza vaccine. Prior vaccination was not associated with a difference in the odds of SARS-CoV-2 infection (3.8% vs. 4.2%, adjusted OR 0.94, 95% CI 0.74-1.19). Prior influenza vaccination was not associated with decreased severity of COVID-19 or lower odds of SARS-CoV-2 infection in pregnancy.
Sections du résumé
BACKGROUND
BACKGROUND
Recent data in nonpregnant individuals suggest a protective effect of influenza vaccination against SARS-CoV-2 infection and its severity.
OBJECTIVES
OBJECTIVE
Our primary objective was to evaluate whether influenza vaccination was associated with COVID-19 severity and pregnancy and neonatal outcomes among those infected with SARS-CoV-2. The secondary objective was to examine the association between influenza vaccination and SARS-CoV-2 infection.
STUDY DESIGN
METHODS
Secondary analysis of a multicenter retrospective cohort of pregnant people who tested positive for SARS-CoV-2 between March and August 2020, and a cohort of random deliveries during the same time period. The associations between 2019 influenza vaccination and the primary outcome of moderate-to-critical COVID-19 as well as maternal and perinatal outcomes were examined among all people who tested positive for SARS-CoV-2 between March and August 2020. The association between 2019 influenza vaccination and having a positive SARS-CoV-2 test was examined among a cohort of individuals who delivered on randomly selected dates between March and August 2020. Univariable and multivariable analyses were performed.
RESULTS
RESULTS
Of 2325 people who tested positive for SARS-CoV-2, 1068 (45.9%) were vaccinated against influenza in 2019. Those who received the influenza vaccine were older, leaner, more likely to have private insurance, and identify as White or Hispanic. They were less likely to smoke tobacco and identify as Black. Overall, 419 (18.0%) had moderate, 193 (8.3%) severe, and 52 (2.2%) critical COVID-19. There was no association between influenza vaccination and moderate-to-critical COVID-19 (29.2% vs. 28.0%, adjusted OR 1.10, 95% CI 0.90-1.34) or adverse maternal and perinatal outcomes among those who tested positive. Of 8152 people who delivered in 2020, 4658 (57.1%) received the influenza vaccine. Prior vaccination was not associated with a difference in the odds of SARS-CoV-2 infection (3.8% vs. 4.2%, adjusted OR 0.94, 95% CI 0.74-1.19).
CONCLUSION
CONCLUSIONS
Prior influenza vaccination was not associated with decreased severity of COVID-19 or lower odds of SARS-CoV-2 infection in pregnancy.
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13896Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
R. J. Martinez‐Portilla, A. Sotiriadis, C. Chatzakis, et al., “Pregnant Women With SARS‐CoV‐2 Infection Are at Higher Risk of Death and Pneumonia: Propensity Score Matched Analysis of a Nationwide Prospective Cohort (COV19Mx),” Ultrasound in Obstetrics & Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology 57, no. 2 (2021): 224–231.
D. Di Mascio, D. Buca, V. Berghella, et al., “Counseling in Maternal‐Fetal Medicine: SARS‐CoV‐2 Infection in Pregnancy,” Ultrasound in Obstetrics & Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology 57 (2021): 687–697.
I. Vojtek, P. Buchy, T. M. Doherty, and B. Hoet, “Would Immunization Be the Same Without Cross‐Reactivity?” Vaccine 37, no. 4 (2019): 539–549.
M. G. Netea, J. Domínguez‐Andrés, L. B. Barreiro, et al., “Defining Trained Immunity and Its Role in Health and Disease,” Nature Reviews Immunology 20, no. 6 (2020): 375–388.
A. Patwardhan and A. Ohler, “The Flu Vaccination May Have a Protective Effect on the Course of COVID‐19 in the Pediatric Population: When Does Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Meet Influenza?” Cureus 2, no. 1 (2021): 1–7.
A. Conlon, C. Ashur, L. Washer, K. A. Eagle, and M. A. Hofmann Bowman, “Impact of the Influenza Vaccine on COVID‐19 Infection Rates and Severity,” American Journal of Infection Control 49, no. 6 (2021): 694–700.
D. Marín‐Hernández, R. E. Schwartz, and D. F. Nixon, “Epidemiological Evidence for Association Between Higher Influenza Vaccine Uptake in the Elderly and Lower COVID‐19 Deaths in Italy,” Journal of Medical Virology 93, no. 1 (2021): 64–65.
M. L. Salem and D. El‐Hennawy, “The Possible Beneficial Adjuvant Effect of Influenza Vaccine to Minimize the Severity of COVID‐19,” Medical Hypotheses 140 (2020): 109752.
G. Fink, N. Orlova‐Fink, T. Schindler, et al., “Inactivated Trivalent Influenza Vaccination is Associated with Lower Mortality Among Patients With COVID‐19 in Brazil,” BMJ Evidence‐Based Medicine, published ahead of print, December 11, 2020, https://doi.org/10.1136/bmjebm-2020-111549.
T. D. Metz, R. G. Clifton, B. L. Hughes, et al., “Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID‐19),” Obstetrics and Gynecology 137, no. 4 (2021): 571–580.
T. D. Metz, R. G. Clifton, B. L. Hughes, et al., “Association of SARS‐CoV‐2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications,” JAMA: Journal of the American Medical Association 327, no. 8 (2022): 748–759.
E. L. Duryea, J. S. Hawkins, D. D. McIntire, B. M. Casey, and K. J. Leveno, “A Revised Birth Weight Reference for the United States,” Obstetrics and Gynecology 124, no. 1 (2014): 16–22.
S. A. Rasmussen, D. J. Jamieson, and T. M. Uyeki, “Effects of Influenza on Pregnant Women and Infants,” American Journal of Obstetrics and Gynecology 207, no. S3 (2012): S3–S8.
W. M. Callaghan, A. A. Creanga, and D. J. Jamieson, “Pregnancy‐Related Mortality Resulting From Influenza in the United States During the 2009–2010 Pandemic,” Obstetrics and Gynecology 126, no. 3 (2015): 486–490.
ACOG Committee on Obstetric Practice. “ACOG Committee Opinion No. 732: Influenza Vaccination During Pregnancy,” Obstetrics and Gynecology 131, no. 4 (2018): e109–e114.
D. B. Fell, E. Azziz‐Baumgartner, M. G. Baker, et al., “Influenza Epidemiology and Immunization During Pregnancy: Final Report of a World Health Organization Working Group,” Vaccine 35, no. 43 (2017): 5738–5750.
D. J. Jamieson, D. M. Kissin, C. B. Bridges, and S. A. Rasmussen, “Benefits of Influenza Vaccination During Pregnancy for pregnant women,” American Journal of Obstetrics and Gynecology 207, no. S3 (2012): S17–S20.
L. D. Arnold, L. Luong, T. Rebmann, and J. J. Chang, “Racial Disparities in U.S. Maternal Influenza Vaccine Uptake: Results from Analysis of Pregnancy Risk Assessment Monitoring System (PRAMS) Data, 2012–2015,” Vaccine 37, no. 18 (2019): 2520–2526.
G. Mor and I. Cardenas, “The Immune System in Pregnancy: A Unique Complexity,” American Journal of Reproductive Immunology 63, no. 6 (2010): 425–433.